Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer
Jazyk angličtina Země Itálie Médium print-electronic
Typ dokumentu hodnotící studie, časopisecké články
Grantová podpora
VEGA grant 1/0380/18
Agentúra Ministerstva školstva, vedy, výskumu a športu SR
PubMed
30661213
DOI
10.1007/s10238-019-00545-y
PII: 10.1007/s10238-019-00545-y
Knihovny.cz E-zdroje
- Klíčová slova
- Colorectal cancer, Droplet digital PCR, KRAS mutation testing, Lymph nodes,
- MeSH
- kolon patologie MeSH
- kolorektální nádory diagnóza genetika patologie MeSH
- lidé MeSH
- lymfatické uzliny patologie MeSH
- molekulární patologie metody MeSH
- mutantní proteiny genetika MeSH
- polymerázová řetězová reakce metody MeSH
- protoonkogen Mas MeSH
- protoonkogenní proteiny p21(ras) genetika MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- hodnotící studie MeSH
- Názvy látek
- KRAS protein, human MeSH Prohlížeč
- MAS1 protein, human MeSH Prohlížeč
- mutantní proteiny MeSH
- protoonkogen Mas MeSH
- protoonkogenní proteiny p21(ras) MeSH
The proto-oncogene KRAS belongs among the most frequently mutated genes in all types of cancer and is also very important oncogene related to colorectal tumors. The detection of mutations in this gene in primary tumor is a predictive biomarker for the anti-EGFR therapy in metastatic CRC (mCRC); however, the patients with wild-type KRAS can also show resistance to the personalized medicine. The droplet-based digital PCR technology has improved the analytical sensitivity of the mutations detection, which led us to the idea about the optimization of this approach for KRAS testing. In this study, we report the application of ddPCR technology in order to analyze the presence of KRAS mutations in primary tumor and matched metastasis in lymph nodes (LNs) from patients with mCRC and address the question, whether the improvement in the detection method can lower the discrepancies of KRAS mutations detection between the primary tumor and regional LNs. Genomic DNA with wtKRAS and commercial DNA with mtKRAS (G12D) were used to set up the ddPCR reaction. Formalin-fixed paraffin-embedded tissues from primary tumor and positive lymph node from 31 patients with mCRC were analyzed using ddPCR and Sanger sequencing. KRAS status of primary tumors was known; however, the mutation status of lymph nodes was not detected previously. From 31 samples of primary tumors, our results corresponded to results from IVD kit in 30 cases. For one patient, ddPCR detected KRAS mutation in comparison with negative result of the IVD kit. In the samples of metastatic infiltrated LNs, ddPCR detected 16 samples as a WT KRAS and 15 lymph nodes showed positivity for KRAS mutation, whereby Sanger sequencing found KRAS mutations in 8 cases only. We also found two cases where genetic conditions of KRAS gene differed between primary tumor and infiltrated lymph node, both "low-grade" adenocarcinoma. Our study approved that ddPCR method is adequate technique with high sensitivity and in the future may be used as a diagnostic tool for evaluation of KRAS mutations, especially in infiltrated LNs of patients with mCRC.
Zobrazit více v PubMed
Carcinogenesis. 2005 May;26(5):916-22 PubMed
Cancer Res. 2006 Apr 15;66(8):3992-5 PubMed
Science. 2006 Sep 29;313(5795):1960-4 PubMed
Virchows Arch. 2008 Nov;453(5):417-31 PubMed
J Clin Oncol. 2010 Mar 1;28(7):1254-61 PubMed
Clin Cancer Res. 2010 Feb 1;16(3):790-9 PubMed
Cancer Metastasis Rev. 2011 Mar;30(1):5-12 PubMed
Gastrointest Cancer Res. 2011 Jan;4(1):15-21 PubMed
Pathol Res Pract. 2011 Jun 15;207(6):399-402 PubMed
Int J Colorectal Dis. 2011 Oct;26(10):1271-7 PubMed
Lab Chip. 2011 Jul 7;11(13):2156-66 PubMed
Anal Chem. 2011 Nov 15;83(22):8604-10 PubMed
Br J Cancer. 2012 Jul 10;107(2):345-51 PubMed
Nature. 2012 Jun 28;486(7404):537-40 PubMed
Virchows Arch. 2013 Mar;462(3):329-35 PubMed
Pathol Res Pract. 2013 Apr;209(4):233-6 PubMed
Science. 2013 Mar 29;339(6127):1546-58 PubMed
J Am Coll Surg. 2013 Aug;217(2):181-90 PubMed
J Pathol. 2014 Jan;232(2):199-209 PubMed
Acta Oncol. 2014 Jul;53(7):852-64 PubMed
Clin Cancer Res. 2015 Mar 1;21(5):1087-97 PubMed
Sci Rep. 2015 Feb 02;5:8065 PubMed
Clin Biochem. 2015 Oct;48(15):948-56 PubMed
PLoS One. 2015 Sep 28;10(9):e0139074 PubMed
Exp Mol Pathol. 2016 Apr;100(2):287-93 PubMed
Int J Cancer. 2016 Aug 1;139(3):647-56 PubMed
Virchows Arch. 2017 Jan;470(1):29-36 PubMed
J Pathol Transl Med. 2017 Jan;51(1):24-31 PubMed
ESMO Open. 2017 Sep 28;2(4):e000235 PubMed
